PRO 140: Phase III ongoing

FDA approved amendments to a double-blind, placebo-controlled, U.S. Phase III trial evaluating 350 mg subcutaneous PRO 140 once weekly plus standard of care antiretroviral therapy (ART) in treatment-e...